LAUSR

The treatment options for patients with aortic valve stenosis (AS) have expanded over the last decade due to the advancement of transcatheter and valve technologies, like the use of sutureless and rapid ‐ deployment valves (SU ‐ AVR) in aortic valve replacement (AVR). In this issue of the Journal of Cardiac Surgery , Morgan and colleagues tried to address important clinical questions using the meta ‐ analysis method to determine the current outcome of SU ‐ AVR for bicuspid aortic valve (BAV) patients across 12 studies; a total of 179 patients were identified after their literature search. 1 The outcomes and complication rates of patients with BAV undergoing SU ‐ AVR with the Perceval sutureless prosthesis (LivaNova) or Edwards Intuity rapid ‐ deployment prosthesis (Edwards Lifesciences) were reviewed. SU ‐ AVR in BAV is controversial due to several reasons such as the anatomy and pathophysiology of BAV, the different character-istics of patients between BAV and tricuspid AS, the possibility of reoperation in the future, and so on. 2